A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 113 participants.
Also called NCT05975905
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 113 participants
- Sponsor
- Keros Therapeutics, Inc.
- Registry
-
NCT05975905
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Brazil, France, Germany, Poland, Portugal, South Korea, Spain, Taiwan, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT05975905. Randomized; quadruple masking; primary purpose treatment. Start 2023-10-17 (actual); primary completion 2025-03-05 (actual). Results posted on 2026-07-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Biological)
- Dose A KER-012
- Intervention (Biological)
- Dose B KER-012
- Intervention (Biological)
- Dose C KER-012
- Intervention (Biological)
- Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks
- Lead sponsor
- Keros Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct05975905- Content hash
73862684713982d758267d3d1083c844ec3115e4293b263e12bd4e051c7dd545